The Independent supplement on Blood disorders – published on the 2nd September (not the 30th Aug as initially planned).

Join the newly formed Cambridge Regional Group – contact us for details – and get a chance to meet-up every 3-4 months. Read more.

The Spring 2011 newsletter is now ready to view on the information material pagehere.

The MDS UK Patient Support Group today expressed its anger and disappointment at the announcement by the Scottish Medicines Consortium that is not recommending Vidaza (azacitidine) be made available through NHS Scotland to patients with a range of life-threatening bone marrow diseases.

'Cancer experts from more than 30 hospitals across Europe have joined a campaign to get an expensive life-extending drug on the NHS', writes Daily Telegraph's medical correspondent Kate Devlin.

London, 26 July 2010 – The MDS UK Patient Support Group has welcomed the decision announced today by the National Institute for Health and Clinical Excellence (NICE) that it will […]

The MDS UK Patient Support Group has announced that it has lodged an appeal against the negative recommendation issued earlier this month by the National Institute for Health and Clinical Excellence (NICE) for the use of Vidaza (azacitidine) in patients with higher-risk myelodysplastic syndrome (MDS).

Only 200 patients helped by £50m fund for extra cancer drugs